Research & Development

Pipeline

Technology Platform

Target Specific and Long-acting Delivery of Proteins
Neutralizing Antibodies Discovery
Industrialization of Recombinant Proteins and Antibodies
Design of Novel Small-molecule Antivirals

Dr. Tao Wang

The CSO of Beijing Kawin Technology and the CEO of Kawin Biosciences USA

Dr. Wang received B.S. degree in Organic Chemistry from Peking University in 1990 and Ph.D. degree in Organic Chemistry from New York University in 1996.From 1996 to 1998, he was a postdoctoral associate with Professor Gilbert Stork at Columbia University.

From 1998 to 2021, Dr. Wang led the discovery of new antiviral and immune-oncology medicines in Bristol-Myers Squibb, both small molecules and peptides.

Among Dr. Wang’s multiple clinical compounds, RukobiaTM (fostemsavir) was approved by the FDA in July 2020 and by EMA in February 2021.

Dr. Wang is the inventor of 101 filed patent applications, among which 75 have been granted in US. Dr. Wang has co-authored 45 peer-reviewed research articles and 6 reviews. Dr. Wang has been the recipient of several awards from Bristol-Myers Squibb Co., including Chemistry Leadership Award, The President’s Award and Innovation Award.

His current responsibilities in Kawin include： 1) overseeing R&D research center, 2) managing Kawin USA subsidiary, 3) building pipeline, 4) fostering external collaborations, and 5) participating in investing activities.

Publications

Discovery and preclinical profiling of GSK3839919, a potent HIV-1 allosteric integrase inhibitor.

Parcella, K.; Wang, T.; Eastman, K.; Zhang, Z.; Yin, Z.; Patel, M.; Tu, Y.; Zheng, B.; Walker, M. A.; Sauliner, M.; Frennesson, D.; Bowsher, M.; Gillis, E.; Peese, K.; Cianci, C.; Dicker, I. B.; McAuliffe, B.; Ding, B.; Falk, P.; Simmermacher, J.; Parker, D. D.; Sivaprakasam, P.; Khan, J. A.; Kish, K.; Lewis, H.; Hanumegowda, U.; Jenkins, S.; Kadow, J. F.; Krystal, M.; Meanwell, N. A. and Naidu, B. N. ACS Med. Chem. Letters 2022, 13, 972.

DOI: 10.1021/acsmedchemlett.2c00115
The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Wang, T.;* Kadow, J. F., Meanwell, N. A. and Krystal, M.Adv. Exp. Med. Biol. 2022, 1366, 45.

DOI: 10.1007/978-981-16-8702-0_4
Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer.

Xu, J.;* Li, X.;* Du, Y.Adv. Biol. (Weinh) 2022, 6(3), e2101065.

DOI: 10.1002/adbi.202101065
Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Wang, T.;* Kadow, J. F. and Meanwell, N. A.*Med. Chem. Res. 2021,30, 1955.

DOI: 10.1007/s00044-021-02787-6
Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.

Gao, Y.;* Kong, F.; Li, G.; Li, C.; Zheng, S.; Lin, J.; Wen, X.; Hu, J.; Wang, X.; Wu, X.; Xing, H.; Jia, J.; Jia, Z.; Guan, Y.; Li, C.; Wu, G.; Gao, Z.; Mou, Z.; Ning, Q.; Mao, Q.; Yang, Y.; Ning, J.; Li, L.; Pan, H.; Zhou, D.; Ding, Y.; Qin, H.; Niu, J.Liver. Int. 2020, 40(11), 2685.

DOI: 10.1111/liv.14633
Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

Rao, H.;* Song, G.;* Li, G.; Yang, Y.; Wu, X.; Guan, Y.; Mao, Q.; Jiang, X.; Wang, C.; Zhang, Y.; Jia, J.; Guo, X.; Li, C.; Ning, J.; Qin, H.; Pan, H.;Wei, L.J. Viral. Hepat. 2020, 27(1), 45.

DOI: 10.1111/jvh.13208

SSE:688687

Research & Development

Pipeline

Technology Platform

Dr. Tao Wang

Publications

Discovery and preclinical profiling of GSK3839919, a potent HIV-1 allosteric integrase inhibitor.

DOI: 10.1021/acsmedchemlett.2c00115

The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Wang, T.;* Kadow, J. F., Meanwell, N. A. and Krystal, M.Adv. Exp. Med. Biol. 2022, 1366, 45.

DOI: 10.1007/978-981-16-8702-0_4

Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer.

Xu, J.;* Li, X.;* Du, Y.Adv. Biol. (Weinh) 2022, 6(3), e2101065.

DOI: 10.1002/adbi.202101065

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Wang, T.;* Kadow, J. F. and Meanwell, N. A.**Med. Chem. Res. 2021,30, 1955.*

DOI: 10.1007/s00044-021-02787-6

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.

Gao, Y.;* Kong, F.; Li, G.; Li, C.; Zheng, S.; Lin, J.; Wen, X.; Hu, J.; Wang, X.; Wu, X.; Xing, H.; Jia, J.; Jia, Z.; Guan, Y.; Li, C.; Wu, G.; Gao, Z.; Mou, Z.; Ning, Q.; Mao, Q.; Yang, Y.; Ning, J.; Li, L.; Pan, H.; Zhou, D.; Ding, Y.; Qin, H.; Niu, J.Liver. Int. 2020, 40(11), 2685.

DOI: 10.1111/liv.14633

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

Rao, H.;* Song, G.;* Li, G.; Yang, Y.; Wu, X.; Guan, Y.; Mao, Q.; Jiang, X.; Wang, C.; Zhang, Y.; Jia, J.; Guo, X.; Li, C.; Ning, J.; Qin, H.; Pan, H.;Wei, L.J. Viral. Hepat. 2020, 27(1), 45.

DOI: 10.1111/jvh.13208

more

Collaborations

+86 10 87120888

Research & Development

Pipeline

Technology Platform

Dr. Tao Wang

Publications

Discovery and preclinical profiling of GSK3839919, a potent HIV-1 allosteric integrase inhibitor.

DOI: 10.1021/acsmedchemlett.2c00115

The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors.

Wang, T.;* Kadow, J. F., Meanwell, N. A. and Krystal, M.Adv. Exp. Med. Biol. 2022, 1366, 45.

DOI: 10.1007/978-981-16-8702-0_4

Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer.

Xu, J.;* Li, X.;* Du, Y.Adv. Biol. (Weinh) 2022, 6(3), e2101065.

DOI: 10.1002/adbi.202101065

Innovation in the discovery of the HIV-1 attachment inhibitor temsavir and its phosphonooxymethyl prodrug fostemsavir.

Wang, T.;* Kadow, J. F. and Meanwell, N. A.*Med. Chem. Res. 2021,30, 1955.

DOI: 10.1007/s00044-021-02787-6

Coblopasvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial.

Gao, Y.;* Kong, F.; Li, G.; Li, C.; Zheng, S.; Lin, J.; Wen, X.; Hu, J.; Wang, X.; Wu, X.; Xing, H.; Jia, J.; Jia, Z.; Guan, Y.; Li, C.; Wu, G.; Gao, Z.; Mou, Z.; Ning, Q.; Mao, Q.; Yang, Y.; Ning, J.; Li, L.; Pan, H.; Zhou, D.; Ding, Y.; Qin, H.; Niu, J.Liver. Int. 2020, 40(11), 2685.

DOI: 10.1111/liv.14633

Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

Rao, H.;* Song, G.;* Li, G.; Yang, Y.; Wu, X.; Guan, Y.; Mao, Q.; Jiang, X.; Wang, C.; Zhang, Y.; Jia, J.; Guo, X.; Li, C.; Ning, J.; Qin, H.; Pan, H.;Wei, L.J. Viral. Hepat. 2020, 27(1), 45.

DOI: 10.1111/jvh.13208

more

Collaborations

+86 10 87120888

Wang, T.;* Kadow, J. F. and Meanwell, N. A.**Med. Chem. Res. 2021,30, 1955.*